Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma. The main questions it aims to answer are: * Objective response rate (ORR) for evaluation * Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS); Total survival time (OS); Safety。

Trial Details

NCT ID
NCT06363006
Phase
PHASE1
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • TKI+Cardunilimab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with histologically/cytologically confirmed hepatocellular carcinoma or cirrhosis meet the clinical diagnostic criteria of the American As…
  • Age ≥18 and ≤75 years old.
  • ECOG physical status score 0 or 1.
  • Barcelona Clinic Liver Cancer (BCLC) stage C; It is not suitable for radical surgery and/or local treatment or stage B that progresses irremediably…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →